# Targeting EphA2 under DNA damage causes mitotic bypass via p21 induction

**Authors:** Ayuka Nakamura, Junna Tanaka, Ryuzaburo Yuki, Yuji Nakayama

PMC · DOI: 10.1016/j.jbc.2026.111271 · 2026-02-06

## TL;DR

This study shows that suppressing EphA2 after DNA damage causes cells to bypass mitosis and form tetraploid cells, reducing cancer cell proliferation.

## Contribution

The novel finding is that EphA2 suppression leads to p21-dependent mitotic bypass and tetraploidization, offering a new therapeutic strategy.

## Key findings

- EphA2 suppression after DNA damage causes mitotic bypass and tetraploidization.
- p21 upregulation is crucial for EphA2 knockdown-induced mitotic bypass in cervical cancer cells.
- Combining EphA2 inhibition with DNA-damaging agents may enhance anti-cancer effects.

## Abstract

EphA2, a receptor tyrosine kinase, is overexpressed in various cancers. Its ligand-independent non-canonical signaling is pro-tumorigenic, and elevated EphA2 expression is associated with poor prognosis in patients. Although preclinical and clinical studies targeting EphA2 have been conducted as cancer therapeutics, its role in the DNA damage response remains elusive. This study examined the role of EphA2 in cell cycle progression in Adriamycin (ADR)-treated cells. ADR treatment transcriptionally upregulated EphA2 expression in a p53-independent manner. Suppression of EphA2 upregulation abrogated G2 arrest, as evidenced by reductions in both cyclin B1 accumulation and Wee1 inhibition-driven cell division. However, the 2N-G1 cell population remained low, with increased tetraploid cells. Time-lapse imaging revealed that tetraploid formation resulted from mitotic bypass rather than mitotic slippage or cytokinesis failure. EphA2 knockdown upregulated p21 expression together with p53, and p21 knockdown suppressed EphA2 knockdown–induced mitotic bypass. Monitoring fluorescence from a green fluorescent protein fusion with the cyclin B1 destruction box demonstrated degradation in interphase without cell division, suggesting premature activation of APC/CCdh1 in interphase. Notably, p21 upregulation following EphA2 knockdown was observed specifically in cervical cancer cell lines. Finally, ADR-induced suppression of cell proliferation was further enhanced by EphA2 knockdown and partially reversed by p21 knockdown. In conclusion, EphA2 suppression induces p21-dependent mitotic bypass and tetraploidization, leading to reduced cell proliferation. EphA2 upregulation following DNA damage may be pro-tumorigenic by maintaining G2 arrest to keep DNA damage at tolerable levels. These findings provide a rationale for combining EphA2 inhibition with DNA-damaging agents in certain cancer types.

## Linked entities

- **Genes:** EPHA2 (EPH receptor A2) [NCBI Gene 1969], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], TP53 (tumor protein p53) [NCBI Gene 7157], CycB (Cyclin B) [NCBI Gene 37618], WEE1 (WEE1 G2 checkpoint kinase) [NCBI Gene 7465]
- **Chemicals:** Adriamycin (PubChem CID 31703), ADR (PubChem CID 31703)
- **Diseases:** cancer (MONDO:0004992), cervical cancer (MONDO:0002974)

## Full-text entities

- **Genes:** WEE1 (WEE1 G2 checkpoint kinase) [NCBI Gene 7465] {aka WEE1A, WEE1hu}, CCNB1 (cyclin B1) [NCBI Gene 891] {aka CCNB}, EPHA2 (EPH receptor A2) [NCBI Gene 1969] {aka ARCC2, CTPA, CTPP1, CTRCT6, ECK}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}
- **Diseases:** tumorigenic (MESH:D002471), cancer (MESH:D009369), cervical cancer (MESH:D002583)
- **Chemicals:** ADR (MESH:D004317)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12972985/full.md

---
Source: https://tomesphere.com/paper/PMC12972985